Patient centricity has rapidly gone from a fringe idea to a fundamental principle across the industry, but are pharma companies missing out on more impactful patient engagement through part
George Underwood looks at the rapid growth of patient centricity over the last few years and considers what pharma’s next steps should be to enhance patient engagement.
Patient and public involvement (PPI) may be increasingly seen as the “right thing to do”, but without systematic evaluation how do we stop good intentions becoming tick-box tokenism?
Oncology is currently a more cutting-edge, dynamic field than it has ever been – as demonstrated at this year’s American Society of Clinical Oncology (ASCO) conference.
